Clinical Trial

A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1

Study acronym: Brilliance NT1
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to measure decreases in daytime sleepiness, cataplexy (sudden loss of muscle tone), and disease symptoms in participants with NT1 when taking ALKS 2680 tablets compared with placebo tablets.
Protocol Amendment History 6 changes
notable Trial sites expanded: 22 -> 29 locations 2026-08-08
notable Trial sites expanded: 17 -> 22 locations 2026-07-03
notable Trial sites expanded: 9 -> 17 locations 2026-06-05
notable Trial sites expanded: 3 -> 9 locations 2026-05-07
critical Recruitment opened 2026-04-22
notable Trial sites expanded: 0 -> 3 locations 2026-04-22
Trial Details
NCT Number NCT07455383
Lead Sponsor Alkermes, Inc.
Conditions Narcolepsy Type 1
Enrollment 150 participants
Start Date 2026-04-06
Primary Completion 2027-05 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-08-07